Why pre-screen biopharmaceutical scientists before the technical seminar and lab panel
Pre-screening biopharmaceutical scientists protects the panel's day, because a technical seminar plus a lab tour costs four or five scientists half a shift. Applicants arrive from academic postdocs, CDMO process development teams, and QC labs, and a CV showing HPLC, AKTA, or bioreactor experience never says who ran the column and who read the report. A ten minute screen shows whether they touched the equipment, which molecule classes they handled, and how they wrote up a deviation.
What actually matters when screening Biopharmaceutical Scientist candidates
- 01
Technique and experimental design
Probe the analytical and process techniques they run themselves, plus the molecule classes they have worked on.
- 02
Results that went somewhere
Look for work that fed a filing, a process transfer, or a clinical decision, not only internal reports.
- 03
Troubleshooting and reproducibility
Test how they handle an assay that stops reproducing right before a submission deadline.
- 04
Documentation and collaboration
Check GMP or GLP documentation habits and how they handle a deviation they caused themselves.
Pre-screening questions to ask Biopharmaceutical Scientist candidates
12 questions grouped by what they test. Ask the same set in every screen and score answers on a consistent scale, or send them as an async video screen and compare answers side by side.
Technique and platforms
5 questions01What analytical techniques are you proficient in, and which ones do you run yourself rather than send out?
Listen forNamed methods with detail: SEC-HPLC, CE-SDS, cIEF, ELISA, LC-MS peptide mapping, plus which instruments and software they operate and the molecules tested.
A generic list of acronyms with no instrument, no molecule class, and no ability to say who ran the method.
02Can you describe your experience with cell culture techniques, including the scales and cell lines you worked with?
Listen forSpecific host systems (CHO, HEK293, insect, microbial), vessel scales from shake flask to stirred-tank bioreactor, feed strategies, and titre or viability numbers they measured.
Only sterile technique basics from a teaching lab, with no fed-batch or perfusion experience and no cell line named.
03What protein purification methods have you used, and how did you choose the capture step?
Listen forAffinity, ion exchange, HIC, and SEC steps with resin names, buffer conditions, load challenge, yield and purity trade-offs, and a reason behind the chosen sequence.
Describes following a written protocol with no view on resin selection, yield, or aggregate removal.
04Walk me through an assay you developed and validated, and the acceptance criteria you set.
Listen forAccuracy, precision, linearity, LOQ and robustness work, ICH Q2 language, system suitability limits, and how the method was transferred to QC or a partner lab.
Assay work that never left development, with no validation protocol, statistics, or acceptance criteria.
05Are you experienced with chromatography systems? Pick one chromatogram you generated and talk me through the peaks.
Listen forNames the system (AKTA, Waters, Agilent) and reads the trace: main peak, aggregates, clipped species, baseline issues, and what they changed next.
Cannot interpret their own trace or describes peaks only as good and bad without impurity identity.
Process and scale-up
3 questions06Have you worked across both upstream and downstream bioprocessing? Tell me where your hands-on depth sits.
Listen forHonest split with detail on one side: bioreactor control parameters and harvest, or capture through final filtration, plus how they hand off to the other team.
Claims full command of both with no unit operation, scale, or control parameter to back it up.
07What is your experience with scale-up from lab to production, and what broke when you scaled?
Listen forConcrete scale jumps with numbers, shear or mixing or mass transfer issues, hold-time and filter sizing changes, and engineering runs with the manufacturing team.
Talks about scale-up in theory only, or claims nothing changed between bench and plant.
08Have you been involved in a tech transfer? Walk me through your part and what the receiving site struggled with.
Listen forNamed documents such as process descriptions, batch records, method transfer protocols, comparability data, plus on-site presence and how gaps were closed.
Sent a protocol over and had no contact with the receiving site or its deviations.
Results and regulatory
2 questions09Can you describe your experience with regulatory submissions and documentation? Which sections did you write?
Listen forSpecific contributions: CMC sections, method validation reports, stability data packages, comparability protocols, and drafting responses to agency questions.
Data that only ever appeared in internal slide decks, with no filing, protocol, or reviewed report.
10How familiar are you with GLP and cGMP in practice, not just in training slides?
Listen forContemporaneous data entry, second-person review, audit trails in the LIMS or ELN, controlled batch records, and experience being questioned during an audit or inspection.
Describes GMP as paperwork or admits to writing up results at the end of the week from memory.
Troubleshooting and records
2 questions11How do you ensure accuracy and reliability when an assay stops reproducing right before a submission deadline?
Listen forSystematic isolation: reference standard, reagent lot, instrument qualification, analyst, plus control charts, retained samples, and a clear escalation to quality and the programme lead.
Repeats the run until the number looks right, or excludes outliers without a documented rationale.
12How do you handle a deviation from an SOP, including one you caused yourself?
Listen forImmediate notification, deviation record raised, product or data impact assessed, root cause investigation, and a CAPA or SOP revision they can name.
Fixed it quietly, blamed equipment or a colleague, or cannot recall any deviation they personally reported.
How to score responses
Score every candidate on the same four criteria immediately after the screen. At this stage you are shortlisting for panel interviews, not making the final call.
Technique and experimental design
35%5Runs their own analytics and process work on real molecule classes, with sound experimental design behind it.
Results that went somewhere
25%5Names work that fed a filing, transfer, or clinical decision, with their own contribution clearly stated.
Troubleshooting and reproducibility
25%5Isolates reproducibility failures methodically under deadline, and will not sign off on data they cannot defend.
Documentation and collaboration
15%5Documents to regulated standard and raises their own deviations promptly rather than quietly correcting them.
Async video lets you watch a scientist narrate a real chromatogram or growth curve on screen, judging how precisely they describe peaks, impurities, and system suitability, something a written CV of techniques never shows.
Try it on HirevireScreening FAQ
Process basics
How long should a pre-screening interview for a biopharmaceutical scientist be?
Ten to fifteen minutes of recorded answers is enough. Give three technique questions, one process or tech transfer question, one deviation or documentation question, and one artefact walkthrough such as a chromatogram or assay qualification summary. Anything longer duplicates the technical seminar, where the panel can probe experimental design and statistics properly.
What should I ask before a candidate talks to the process development team?
Ask what they personally operated: bioreactor scale and control platform, chromatography skids such as AKTA or ProA capture steps, and the analytical methods they qualified. Then ask which molecule classes, monoclonals, fusion proteins, viral vectors, or peptides. This lets the process development team start at design questions instead of confirming basic hands-on scope.
Evaluating answers
How can I tell if a biopharmaceutical scientist actually ran the experiments?
Listen for operating detail a supervisor would not carry: buffer conditions, resin choice, load challenge, system suitability limits, column repacking, or why a run was aborted. Candidates who only reviewed data speak in outcomes and titres. Ask one follow-up on a number they quote; hands-on scientists explain how it was measured.
What is a red flag when a candidate describes a deviation?
The red flag is a deviation story with no paperwork and no owner. Strong answers name the SOP section missed, when quality was notified, the investigation outcome, and the CAPA or SOP revision that followed. Candidates who blame equipment, a colleague, or say they simply repeated the run will struggle in a GMP-regulated lab.
Go deeper on this role
Sanat has been hiring since 2012 and watching the recruitment industry change up close ever since, and turned that screening process into Hirevire's video screening platform. LinkedIn
